康泰医学：股东王桂丽计划减持公司股份不超过400万股

Summary of Key Points Core Viewpoint - 康泰医学 plans to reduce shareholding by major shareholders, which may impact stock performance and investor sentiment [1][2]. Group 1: Shareholding Reduction Plans - Major shareholder 王桂丽 holds approximately 47.13 million shares (11.73% of total shares) and plans to reduce holdings by up to 4 million shares (1% of total shares) through centralized bidding and up to 8 million shares (1.99% of total shares) via block trading within three months after the announcement [1]. - Directors 杨志山 and 高瑞斌 plan to reduce their holdings by up to 540,000 shares (0.13% of total shares) and 300,000 shares (0.07% of total shares) respectively through centralized bidding [1]. - Other senior management members also plan to reduce their holdings by various amounts, with the total reduction for any shareholder not exceeding 1% through centralized bidding and 2% through block trading within any 90-day period [1]. Group 2: Company Financials - 康泰医学's revenue composition for 2024 is projected to be 99.22% from the medical device industry and 0.78% from other businesses [2]. - The current market capitalization of 康泰医学 is 8.3 billion yuan [2].